Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN).
Lodise TP, Van Wart S, Sund ZM, Bressler AM, Khan A, Makley AT, Hamad Y, Salata RA, Silveira FP, Sims MD, Kabchi BA, Saad MA, Brown C, Oler RE Jr, Fowler V Jr, Wunderink RG. Lodise TP, et al. Among authors: wunderink rg. Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01809-20. doi: 10.1128/AAC.01809-20. Print 2021 Feb 17. Antimicrob Agents Chemother. 2021. PMID: 33168615 Free PMC article. Clinical Trial.
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
Fink MP, Snydman DR, Niederman MS, Leeper KV Jr, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, et al. Fink MP, et al. Among authors: wunderink rg. Antimicrob Agents Chemother. 1994 Mar;38(3):547-57. doi: 10.1128/AAC.38.3.547. Antimicrob Agents Chemother. 1994. PMID: 8203853 Free PMC article. Clinical Trial.
Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia.
Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C. Drusano GL, et al. Among authors: wunderink rg. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01323-17. doi: 10.1128/AAC.01323-17. Print 2018 Jan. Antimicrob Agents Chemother. 2017. PMID: 29038277 Free PMC article.
The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).
Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Bleasdale SC, Schultz S, Barron M, Stapleton A, Wray D, Chambers H, Fowler VG, Holland TL. Lodise TP, et al. Among authors: wunderink rg. Clin Infect Dis. 2020 Apr 10;70(8):1536-1545. doi: 10.1093/cid/ciz460. Clin Infect Dis. 2020. PMID: 31157370 Free PMC article.
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Among authors: wunderink rg. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
Multicenter Evaluation of the Unyvero Platform for Testing Bronchoalveolar Lavage Fluid.
Klein M, Bacher J, Barth S, Atrzadeh F, Siebenhaller K, Ferreira I, Beisken S, Posch AE, Carroll KC, Wunderink RG, Qi C, Wu F, Hardy DJ, Patel R, Sims MD. Klein M, et al. Among authors: wunderink rg. J Clin Microbiol. 2021 Feb 18;59(3):e02497-20. doi: 10.1128/JCM.02497-20. Print 2021 Feb 18. J Clin Microbiol. 2021. PMID: 33328178 Free PMC article.
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
Martin-Loeches I, Timsit JF, Kollef MH, Wunderink RG, Shime N, Nováček M, Kivistik Ü, Réa-Neto Á, Bruno CJ, Huntington JA, Lin G, Jensen EH, Motyl M, Yu B, Gates D, Butterton JR, Rhee EG. Martin-Loeches I, et al. Among authors: wunderink rg. J Antimicrob Chemother. 2022 Mar 31;77(4):1166-1177. doi: 10.1093/jac/dkab494. J Antimicrob Chemother. 2022. PMID: 35022730 Free PMC article. Clinical Trial.
348 results